AstraZeneca CEO Brennan Talks About Cutting Deals and Dealing With Change
PhRMA's new chairman, AstraZeneca CEO David Brennan, wants to make a deal on health reform - but not necessarily the kind of tradeoff the industry made on the Medicare drug benefit
You may also be interested in...
Formally at the user fee negotiation table for the first time, the advocacy group wants new drugs to be tested against the "best practice" for treating a disease.
Merck's acquisition of Schering-Plough is all about buying breathing room, relief from what looks to be a 4-year, 50% earnings decline as key products go generic. Moreover, the relief comes relatively inexpensively (unless J&J steps in with a counteroffer), a fact that reflects Schering's lack of strategic options. In this interview, Merck's R&D boss Peter Kim and chief strategist, Mervyn Turner, explain the key pipeline and marketing complementarities and cost-cutting possibilities which prompted the deal -- and how they plan to integrate the two businesses.
Current R&D strategy emphasizes improvements to R&D processes, like trying to reduce costs and cycle time. Making go/no-go decisions earlier on is also a goal, R&D execs say in an interview. The firm is in a building phase as it makes up for some major Phase III failures in recent years. AstraZeneca's current late-stage pipeline is mostly focused on lifecycle management